Description
JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis
Article: JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis
€2.42
Related products
-
Article: Highlights in squamous cell carcinoma of the head and neck
€2.42 Add to cart -
1 year access Online Belgian Journal of Hematology (BJH)
€43.60 Add to cart -
Article: INTRODUCTION
€2.42 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€2.42 Add to cart
